Amundi's Quick-Fire Trade and a Quiet Retreat on Tariffs: The Two Stories Shaping Bayer's Week

Bayer shares swing as Amundi briefly crosses 3% stake threshold, while Monsanto withdraws Chinese glyphosate tariff bid amid Supreme Court Roundup case.

Bayer’s shares have been on a rollercoaster this month, but the latest headlines reveal a company navigating both micro-level fund mechanics and macro-level legal strategy. While a major European asset manager briefly crossed the 3% threshold in Bayer stock only to slip back below it within days, the pharmaceuticals and agriculture group also quietly withdrew a controversial tariff application on Chinese glyphosate imports. Together, the two developments paint a picture of a stock caught between short-term technical noise and longer-term legal repositioning.

The Amundi Flip-Flop: Technical, Not Strategic

On July 8, Amundi, one of Europe’s largest asset managers, held 30,375,174 Bayer voting rights, equivalent to 3.09% of the total 982,424,082 shares. That crossing of the 3% reporting threshold was disclosed on July 14. But just days later, the French firm’s stake slipped to 2.96%, triggering a second notification on July 21. Net movement: roughly 0.13 percentage points.

Such rapid crossings are rarely the result of a deliberate strategic pivot. More often, they stem from technical factors within complex fund structures. Amundi manages Bayer exposure across numerous subsidiaries and investment vehicles, each buying and selling independently. When aggregated, these individual trades can push the total stake over or under a reporting threshold without signaling any unified conviction about the stock’s prospects.

The timing is notable. Bayer shares hit a 52-week high of €53.86 on July 3, but have since retreated nearly 13% to around €46.98. Over the past twelve months, the stock has still gained almost 69%, so the recent pullback looks more like profit-taking after a blistering rally than a change in fundamentals. Institutional investors often tighten their position management during such corrections, and Amundi’s back-and-forth fits that pattern.

Tariff Retreat: A Win for Farmers, a Pivot for Bayer

On a separate front, Bayer’s subsidiary Monsanto withdrew its application for antidumping duties on Chinese glyphosate imports on July 21. The company had originally sought tariffs ranging from 68.9% to 446.47% — a move that drew sharp opposition from U.S. agricultural groups. The National Corn Growers Association, the American Soybean Association, and the National Association of Wheat Growers all welcomed the withdrawal, which they argued would keep herbicide costs in check for their members.

Bayer’s Ruveon unit said it would maintain its dynamic pricing model, which adjusts to market conditions. The retreat defuses a potential conflict between Bayer’s trade interests and its customer base on American farms.

The Bigger Picture: A Supreme Court Showdown

While the tariff issue has been resolved for now, the far more consequential legal battle continues. The U.S. Supreme Court is weighing whether federal law preempts state-level lawsuits against Bayer over its Roundup herbicide. A ruling in Bayer’s favor could cap future damages from thousands of pending cases. The hearings have drawn political heat, with activists from the “MAHA moms” movement protesting and threatening electoral consequences if the court sides with Bayer. U.S. Health Secretary Robert F. Kennedy Jr. has publicly stated that glyphosate causes cancer, adding to the charged atmosphere.

Adding another layer of uncertainty, the U.S. Environmental Protection Agency is scheduled to review glyphosate in October 2026, which could further shift the legal landscape.

Market Reaction: Calm Amid the Noise

Despite the flurry of news, Bayer shares have held relatively steady. The stock currently trades at €47.78, up 29.10% year-to-date, but still 11.29% below the July high. The market appears to be pricing in hope that the Supreme Court will provide legal relief, while treating the tariff retreat as a modest positive for customer relations. For now, the rally’s sustainability hinges on the Court’s decision — and on whether institutional investors like Amundi see the current pullback as a buying opportunity or a reason to stay on the sidelines.